NEKTAR THERAPEUTICS (NKTR) Stock Analyst Ratings
USA - NASDAQ:NKTR - US6402683063 - Common Stock
60.35 USD
+1.18 (+1.99%)
60.93 USD
+0.58 (+0.96%)
ChartMill assigns a Buy % Consensus number of 81% to NKTR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 95.04. This target is 57.49% above the current price.
NKTR was analyzed by 14 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about NKTR.
In the previous month the buy percentage consensus was at a similar level.
NKTR was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-23 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-09-19 | BTIG | Reiterate | Buy -> Buy |
| 2025-07-08 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-06-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-11 | Jefferies | Upgrade | Hold -> Buy |
| 2025-03-14 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-08 | B. Riley Securities | Initiate | Buy |
| 2024-11-04 | Piper Sandler | Initiate | Overweight |
| 2024-03-06 | Jefferies | Maintains | Hold -> Hold |
| 2023-11-20 | JP Morgan | Reiterate | Underweight |
| 2023-11-09 | TD Cowen | Upgrade | Market Perform -> Outperform |
| 2023-08-07 | Mizuho | Reiterate | Neutral |
| 2023-05-10 | Jefferies | Upgrade | Underperform -> Hold |
| 2023-03-06 | Oppenheimer | Maintains | Perform |
| 2023-02-27 | Goldman Sachs | Maintains | Sell |
| 2023-02-24 | SVB Leerink | Maintains | Market Perform |
| 2023-02-24 | Jefferies | Downgrade | Hold -> Underperform |
| 2022-08-08 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2022-04-18 | Mizuho | Maintains | Neutral |
| 2022-04-18 | SVB Leerink | Maintains | Market Perform |
| 2022-04-18 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2022-03-09 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2021-11-08 | Benchmark | Upgrade | Hold -> Buy |
| 2021-11-08 | SVB Leerink | Maintains | Market Perform |
| 2021-11-05 | Oppenheimer | Maintains | Perform |
| 2021-09-10 | B of A Securities | Initiate | Neutral |
| 2021-08-06 | SVB Leerink | Maintains | Market Perform |
NEKTAR THERAPEUTICS / NKTR FAQ
Can you provide the average price target for NEKTAR THERAPEUTICS stock?
14 analysts have analysed NKTR and the average price target is 95.04 USD. This implies a price increase of 57.49% is expected in the next year compared to the current price of 60.35.
How do analysts rate NEKTAR THERAPEUTICS (NKTR)?
The consensus rating for NEKTAR THERAPEUTICS (NKTR) is 81.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed NEKTAR THERAPEUTICS (NKTR)?
The number of analysts covering NEKTAR THERAPEUTICS (NKTR) is 14.